Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Auger

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Clinical Proteomics|October 17, 2018
Quality assessment and interference detection in targeted mass spectrometry data using machine learningShadi Toghi Eshghi, Paul Auger, W Rodney Mathews
Proteomics. Clinical Applications|December 8, 2010
Cancer biomarker discovery via low molecular weight serum proteome profiling - Where is the tumor?Michael T Davis, Paul Auger, Chris Spahr, et al.
Scientific Reports|November 15, 2018
Calpain-mediated tau fragmentation is altered in Alzheimer's disease progressionHsu-Hsin Chen, Peter Liu, Paul Auger, et al.
Biorxiv : the Preprint Server for Biology|February 26, 2024
Alterations in Lysosomal, Glial and Neurodegenerative Biomarkers in Patients with Sporadic and Genetic Forms of Frontotemporal DementiaJennifer Hsiao-Nakamoto, Chi-Lu Chiu, Lawren VandeVrede, et al.
Journal of Medicinal Chemistry|February 1, 2024
Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton's Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell MalignanciesDaniel W Robbins, Mark A Noviski, Ying Siow Tan, et al.
Science (New York, N.Y.)|February 1, 2024
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127Skye Montoya, Jessie Bourcier, Mark Noviski, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Clinical Proteomics|October 17, 2018
Quality assessment and interference detection in targeted mass spectrometry data using machine learningShadi Toghi Eshghi, Paul Auger, W Rodney Mathews
Proteomics. Clinical Applications|December 8, 2010
Cancer biomarker discovery via low molecular weight serum proteome profiling - Where is the tumor?Michael T Davis, Paul Auger, Chris Spahr, et al.
Scientific Reports|November 15, 2018
Calpain-mediated tau fragmentation is altered in Alzheimer's disease progressionHsu-Hsin Chen, Peter Liu, Paul Auger, et al.
Biorxiv : the Preprint Server for Biology|February 26, 2024
Alterations in Lysosomal, Glial and Neurodegenerative Biomarkers in Patients with Sporadic and Genetic Forms of Frontotemporal DementiaJennifer Hsiao-Nakamoto, Chi-Lu Chiu, Lawren VandeVrede, et al.
Journal of Medicinal Chemistry|February 1, 2024
Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton's Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell MalignanciesDaniel W Robbins, Mark A Noviski, Ying Siow Tan, et al.
Science (New York, N.Y.)|February 1, 2024
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127Skye Montoya, Jessie Bourcier, Mark Noviski, et al.
Pageof 1